Literature DB >> 2872945

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

C A Altar, A M Wasley, R F Neale, G A Stone.   

Abstract

In thin sections of rat brain, [3H]spiperone binds to D2 sites in the basal ganglia (caudate-putamen, nucleus accumbens, olfactory tubercle) and S2 sites in the claustrum and motor cortex. The in vitro displacement of [3H]spiperone from these regions was quantified autoradiographically with the "atypical" neuroleptics clozapine and thioridazine, which ameliorate psychosis, a "typical" neuroleptic, haloperidol, which also induces extrapyramidal side effects, or with metoclopramide, which induces extrapyramidal side effects but is an ineffective antipsychotic. Whereas metoclopramide was equipotent at D2 sites, haloperidol was less potent and clozapine and thioridazine more potent by 2- to 3-fold at competing for D2 sites in the nucleus accumbens or olfactory tubercle than in the caudate-putamen. As measured autoradiographically or with tissue homogenates, clozapine, thioridazine, and five other atypical neuroleptics were 4- to 800-times more potent at competing for S2 sites in the frontal cortex than for D2 sites in the basal ganglia. A preference of atypical antipsychotics for D2 receptors in the nucleus accumbens and olfactory tubercle and for the S2 receptor may explain the relative lack of extrapyramidal side effects produced by these compounds.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872945     DOI: 10.1016/0361-9230(86)90181-4

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  31 in total

1.  Cognition, schizophrenia, and the atypical antipsychotic drugs.

Authors:  H Y Meltzer; S Park; R Kessler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Distribution of D2 dopamine receptor mRNA in rat brain.

Authors:  J H Meador-Woodruff; A Mansour; J R Bunzow; H H Van Tol; S J Watson; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

5.  Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species.

Authors:  M Camps; P H Kelly; J M Palacios
Journal:  J Neural Transm Gen Sect       Date:  1990

6.  Differential effects of dopamine receptor antagonists on the sexual behavior of male rats.

Authors:  J G Pfaus; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Seroquel: electrophysiological profile of a potential atypical antipsychotic.

Authors:  J M Goldstein; L C Litwin; E B Sutton; J B Malick
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 9.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

Review 10.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.